Thus, we have focused on studying whether inactivation of erbB3 signaling with MM-121 may specifically downregulate Survivin, and subsequently re-sensitize the otherwise resistant breast cancer cells to paclitaxel-mediated anti-proliferative/anti-survival effects and apoptosis. This evidence concerns the gene ERBB3 and breast carcinoma.